利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1225 条记录 (耗时 0.033 秒)

    GENE EXPRESSION SIGNATURES FOR STAGING AND PROGNOSIS OF PROSTATE, BREAST AND LEUKEMIA CANCERS
    101.
    发明申请
    GENE EXPRESSION SIGNATURES FOR STAGING AND PROGNOSIS OF PROSTATE, BREAST AND LEUKEMIA CANCERS 审中-公开
    用于分期和预防前列腺癌，乳腺癌和白血病癌症的基因表达标志

    公开(公告)号：US20140377220A1

    公开(公告)日：2014-12-25

    申请号：US14360029

    申请日：2012-11-21

    申请人： UTI LIMITED PARTNERSHIP

    发明人： Tarek A. Bismar

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57496

    摘要： The present invention is drawn to methods of assessing and treating cancers such as ERG-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (HSTG3); lymphoid enhancer-binding protein factor 1 (LEF1); frizzled-related protein (FRZB); annexin A4 (ANXA4); Meis homeobox 2 (MEIS2); syndecan binding protein (syntenin) (SDCBP); ankyrin 3, node of Ranvier (ankyrin G) (ANK3); chromodomain helicase DNA binding protein 5 (CHD5); phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7); and wingless-type MMTV integration site family member 2 (WNT2).

    摘要翻译： 本发明涉及通过检查在该疾病状态中失调的特定基因的组合的表达来评估和治疗癌症如ERG相关性，前列腺，乳腺和白血病的方法。 基因的组合选自以下基因：生长家族抑制剂，成员3（HSTG3）; 淋巴增强结合蛋白因子1（LEF1）; 卷曲相关蛋白（FRZB）; 膜联蛋白A4（ANXA4）; Meis homeobox 2（MEIS2）; syndecan结合蛋白（syntenin）（SDCBP）; 锚蛋白3，Ranvier（ankyrin G）（ANK3）的结点; 染色体解旋酶DNA结合蛋白5（CHD5）; 磷脂酶A2，第VII组（血小板激活因子乙酰水解酶，血浆）（PLA2G7）; 和无翼型MMTV集成站点家庭成员2（WNT2）。

    Individualized cancer therapy
    102.
    发明授权
    Individualized cancer therapy 有权

    公开(公告)号：US08916530B2

    公开(公告)日：2014-12-23

    申请号：US12609462

    申请日：2009-10-30

    申请人： David Shanahan ,  John Nemunaitis ,  Neil Senzer ,  Phillip Maples ,  Donald Rao

    发明人： David Shanahan ,  John Nemunaitis ,  Neil Senzer ,  Phillip Maples ,  Donald Rao

    IPC分类号： A01N43/04 ,  A61K31/713 ,  C12N15/113 ,  C07H21/04

    CPC分类号： C12N15/1135 ,  A61K9/1273 ,  A61K9/513 ,  A61K31/7105 ,  A61K31/713 ,  A61K48/00 ,  A61K48/005 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/32 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57496 ,  G01N2800/52

    摘要： In certain embodiments, the invention provides methods for treating cancer, comprising: (a) obtaining a specimen of cancer tissue and normal tissue from a patient; (b) extracting total protein and RNA from the cancer tissue and normal tissue; (c) obtaining a protein expression profile of the cancer tissue and normal tissue; (d) identifying over-expressed proteins in the cancer tissue; (e) comparing the protein expression profile to a gene expression profile; (f) identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins; (g) designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein; (h): designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component; (i) incorporating the first cassette into a first delivery vehicle; (j) providing a patient with an effective amount of the first delivery vehicle; (k) extracting total protein and RNA from the treated cancer tissue; (l) identifying over-expressed proteins in the treated cancer tissue; (m) designing a second RNA interference expression cassette to modulate the expression of a second prioritized protein in the treated tissue; (n) incorporating the second cassette into a second delivery vehicle; (o) providing the previously treated patient with an effective amount of the second delivery vehicle; (p) identifying a novel protein signal following prior treatment with protein specific knockdown; (q) identifying a gene mutation provided by gene sequencing/microarray on assessment of other protein signals; and (r) identifying of a novel protein signal as a result of determination of the gene mutation and assessment of other protein signals to, directly or indirectly, modify the expression (i.e., production) of such proteins.

    HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA
    103.
    发明申请
    HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA 审中-公开
    HISTONE DEACETYLASE（HDAC）生物标志物在多种MYELOMA

    公开(公告)号：US20140357512A1

    公开(公告)日：2014-12-04

    申请号：US14294833

    申请日：2014-06-03

    申请人： ACETYLON PHARMACEUTICALS, INC.

    发明人： Min Yang ,  Simon S. Jones

    IPC分类号： G01N33/574 ,  G01N33/50

    CPC分类号： G01N33/57407 ,  C12N9/16 ,  G01N33/5011 ,  G01N33/57426 ,  G01N33/57496 ,  G01N2333/98 ,  G01N2440/10 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2800/52

    摘要： The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

    摘要翻译： 本发明涉及多发性骨髓瘤中的组蛋白脱乙酰酶（HDAC）生物标志物。 具体地，生物标志物是药物特异性的，用于多发性骨髓瘤的乙酰化的组蛋白脱乙酰酶（HDAC）或HDAC6生物标记肽。 或者，生物标志物是用于多发性骨髓瘤的药物特异性的HDAC6生物标记肽，其被乙酰化或未乙酰化。 本发明还涉及包含检测剂的试剂盒和用于鉴定本发明的生物标志物肽的说明书。 本发明还涉及用于监测受试者中HDAC抑制剂的治疗效率的方法。

    HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER
    105.
    发明申请
    HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER 审中-公开

    公开(公告)号：US20140329905A1

    公开(公告)日：2014-11-06

    申请号：US14366242

    申请日：2012-12-21

    申请人： Deutsches Krebsforschungszentrum

    发明人： Ina Oehme ,  Olaf Witt ,  Nathan Brady

    IPC分类号： C12Q1/68 ,  A61K45/06 ,  G01N33/574 ,  A61K31/165

    CPC分类号： C12Q1/6881 ,  A61K31/165 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  C12Q2600/106 ,  G01N33/57407 ,  G01N33/57496 ,  G01N2333/47 ,  G01N2800/52 ,  G01N2800/54 ,  A61K2300/00

    摘要： The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an autophagy-related gene 4D (ATG4D) product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor. Moreover, The present invention relates to a method of predicting the risk of recurrence and/or progression of a cancer in an subject treated by cancer therapy, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an ATG4D product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) predicting the risk of recurrence and/or progression of a cancer treated by cancer therapy. The present invention also relates to a device for identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor, a kit adapted to carry out the method of the present invention. Finally, the invention relates to 2-(4-butoxyphenyl)-N-hydroxyacetamide (bufexamac) for use in treating cancer in a subject, wherein said bufexamac is to be applied in a co-treatment with cancer therapy.

    摘要翻译： 本发明涉及鉴定易于与组蛋白脱乙酰酶10（HDAC10）抑制剂共同治疗的受试者的方法，所述受试者需要和/或治疗针对癌症的癌症治疗，所述方法包括以下步骤 a）确定来自所述受试者的癌症样品中的HDAC10基因产物和/或自噬相关基因4D（ATG4D）产物的量，b）将步骤a）中测定的所述HDAC10基因产物的量与 所述HDAC10基因产物的参考量和/或在步骤a）中测定的ATG4D产物的量具有所述ATG4D产物的参考量，以及c）鉴定易于与HDAC10抑制剂共同处理的受试者。 此外，本发明涉及一种预测通过癌症治疗治疗的受试者中癌症复发和/或进展的风险的方法，包括以下步骤：a）确定HDAC10基因产物和/或ATG4D产物的量 在来自所述受试者的癌症样品中，b）比较步骤a）中测定的所述HDAC10基因产物的量与所述HDAC10基因产物的参考量和/或在步骤a）中测定的ATG4D产物的量与参考 所述ATG4D产品的量，以及c）预测通过癌症治疗治疗的癌症的复发和/或进展的风险。 本发明还涉及用于鉴定易于与HDAC10抑制剂共同处理的受试者的装置，适用于实施本发明方法的试剂盒。 最后，本发明涉及用于治疗受试者中的癌症的2-（4-丁氧基苯基）-N-羟基乙酰胺（bufexamac），其中所述的bufexamac与癌症疗法共同使用。

    Assay For Predictive Biomarkers Of Anti-Estrogen Efficacy
    109.
    发明申请
    Assay For Predictive Biomarkers Of Anti-Estrogen Efficacy 审中-公开
    测定抗雌激素功效的预测生物标志物

    公开(公告)号：US20140296198A1

    公开(公告)日：2014-10-02

    申请号：US14355335

    申请日：2012-11-01

    申请人： Invivis Pharmaceuticals Inc.

    发明人： Erard Gilles

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57492 ,  G01N33/57496 ,  G01N2333/723 ,  G01N2500/10

    摘要： Biomarkers associated with anti-estrogen sensitivity in cancers, methods for detecting and quantitating the biomarkers, and methods for treating cancer patients that exhibit the biomarkers are provided. The biomarkers are activated estrogen receptor foci (AEF) found in the nuclei of certain tumor cells. The methods provide new information to guide the intention to treat patients with anti-estrogens, allowing selection of individual patients and patient populations that are likely to respond to treatment. Also provided are methods for screening an antitumor drug or antitumor drug candidate for AEF inactivating activity. Such methods are useful to identify additional AEF-active drugs, including anti-estrogens, which may be candidates for use in treating AEF-positive tumors according to the methods of the invention.

    摘要翻译： 提供了与癌症中抗雌激素敏感性相关的生物标志物，用于检测和定量生物标志物的方法，以及用于治疗展现生物标志物的癌症患者的方法。 生物标志物是在某些肿瘤细胞核中发现的活化的雌激素受体灶（AEF）。 这些方法提供了新的信息来指导治疗患有抗雌激素的患者的意图，允许选择可能对治疗有反应的个体患者和患者群体。 还提供了用于筛选用于AEF灭活活性的抗肿瘤药物或抗肿瘤药物候选物的方法。 这些方法对于鉴定另外的AEF活性药物（包括抗雌激素）是有用的，其可以是根据本发明的方法用于治疗AEF阳性肿瘤的候选物。